Biodexa Free Cash Flow Yield vs Cash Flow To Debt Ratio Analysis

BDRX Stock

4.35 0.19 4.57%

Biodexa Pharmaceticals financial indicator trend analysis is way more than just evaluating Biodexa Pharmaceticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biodexa Pharmaceticals is a good investment. Please check the relationship between Biodexa Pharmaceticals Free Cash Flow Yield and its Cash Flow To Debt Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Free Cash Flow Yield vs Cash Flow To Debt Ratio

Free Cash Flow Yield vs Cash Flow To Debt Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biodexa Pharmaceticals Free Cash Flow Yield account and Cash Flow To Debt Ratio. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Biodexa Pharmaceticals' Free Cash Flow Yield and Cash Flow To Debt Ratio is 0.42. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Cash Flow To Debt Ratio in the same time period over historical financial statements of Biodexa Pharmaceticals, assuming nothing else is changed. The correlation between historical values of Biodexa Pharmaceticals' Free Cash Flow Yield and Cash Flow To Debt Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Biodexa Pharmaceticals are associated (or correlated) with its Cash Flow To Debt Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Flow To Debt Ratio has no effect on the direction of Free Cash Flow Yield i.e., Biodexa Pharmaceticals' Free Cash Flow Yield and Cash Flow To Debt Ratio go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Cash Flow To Debt Ratio

Most indicators from Biodexa Pharmaceticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.65 in 2025, whereas Selling General Administrative is likely to drop slightly above 3.9 M in 2025.

Biodexa Pharmaceticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Net Receivables	Short Term Debt	Common Stock	Inventory	Net Tangible Assets	Common Stock Shares Outstanding
Total Assets		0.35	0.67	0.99	0.84	-0.72	0.18	0.7	0.81	0.96	0.59	-0.32	0.81	0.66	0.66	-0.07	0.72	0.88	0.94	0.28	0.63	-0.29	-0.35	0.46	-0.34	-0.33
Other Current Liab	0.35		0.84	0.25	0.24	-0.06	0.23	0.15	0.02	0.48	-0.22	-0.34	0.02	0.35	0.12	-0.2	0.66	0.07	0.44	0.12	0.68	0.11	0.0	0.26	-0.06	0.06
Total Current Liabilities	0.67	0.84		0.55	0.6	-0.21	0.25	0.65	0.28	0.77	0.3	-0.33	0.28	0.65	0.47	-0.2	0.91	0.37	0.71	0.42	0.76	0.05	-0.17	0.42	-0.26	-0.12
Total Stockholder Equity	0.99	0.25	0.55		0.82	-0.79	0.12	0.63	0.86	0.91	0.56	-0.28	0.86	0.55	0.62	-0.01	0.6	0.92	0.9	0.18	0.58	-0.36	-0.33	0.4	-0.3	-0.31
Property Plant And Equipment Net	0.84	0.24	0.6	0.82		-0.38	0.22	0.79	0.53	0.87	0.69	-0.43	0.53	0.63	0.86	-0.14	0.66	0.63	0.79	0.53	0.56	-0.12	-0.54	0.62	-0.45	-0.54
Net Debt	-0.72	-0.06	-0.21	-0.79	-0.38		-0.03	-0.29	-0.97	-0.51	-0.23	0.05	-0.97	-0.14	-0.1	-0.08	-0.19	-0.93	-0.55	0.16	-0.24	0.39	0.11	-0.12	0.07	0.05
Retained Earnings	0.18	0.23	0.25	0.12	0.22	-0.03		0.14	0.06	0.21	0.13	-0.91	0.06	0.41	0.35	-0.96	0.35	0.06	0.2	0.5	-0.02	0.86	-0.69	0.73	-0.71	-0.67
Accounts Payable	0.7	0.15	0.65	0.63	0.79	-0.29	0.14		0.46	0.72	0.82	-0.13	0.46	0.7	0.69	-0.06	0.73	0.53	0.65	0.64	0.4	-0.06	-0.39	0.41	-0.38	-0.39
Cash	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46		0.61	0.43	-0.08	1.0	0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Assets Total	0.96	0.48	0.77	0.91	0.87	-0.51	0.21	0.72	0.61		0.58	-0.38	0.61	0.74	0.76	-0.13	0.83	0.71	0.98	0.33	0.69	-0.21	-0.35	0.5	-0.37	-0.34
Non Currrent Assets Other	0.59	-0.22	0.3	0.56	0.69	-0.23	0.13	0.82	0.43	0.58		-0.14	0.43	0.61	0.78	-0.07	0.48	0.48	0.57	0.59	0.14	-0.08	-0.39	0.27	-0.46	-0.4
Other Assets	-0.32	-0.34	-0.33	-0.28	-0.43	0.05	-0.91	-0.13	-0.08	-0.38	-0.14		-0.08	-0.42	-0.52	0.87	-0.38	-0.12	-0.35	-0.47	-0.19	-0.7	0.73	-0.8	0.71	0.73
Cash And Short Term Investments	0.81	0.02	0.28	0.86	0.53	-0.97	0.06	0.46	1.0	0.61	0.43	-0.08		0.31	0.26	0.05	0.32	0.99	0.63	0.05	0.34	-0.38	-0.19	0.22	-0.17	-0.14
Non Current Liabilities Total	0.66	0.35	0.65	0.55	0.63	-0.14	0.41	0.7	0.31	0.74	0.61	-0.42	0.31		0.68	-0.36	0.89	0.38	0.74	0.7	0.44	0.14	-0.48	0.55	-0.48	-0.48
Other Current Assets	0.66	0.12	0.47	0.62	0.86	-0.1	0.35	0.69	0.26	0.76	0.78	-0.52	0.26	0.68		-0.3	0.61	0.36	0.74	0.54	0.3	0.07	-0.59	0.55	-0.57	-0.58
Other Stockholder Equity	-0.07	-0.2	-0.2	-0.01	-0.14	-0.08	-0.96	-0.06	0.05	-0.13	-0.07	0.87	0.05	-0.36	-0.3		-0.31	0.05	-0.12	-0.46	0.08	-0.87	0.63	-0.65	0.76	0.62
Total Liab	0.72	0.66	0.91	0.6	0.66	-0.19	0.35	0.73	0.32	0.83	0.48	-0.38	0.32	0.89	0.61	-0.31		0.41	0.79	0.6	0.67	0.09	-0.31	0.52	-0.4	-0.28
Total Current Assets	0.88	0.07	0.37	0.92	0.63	-0.93	0.06	0.53	0.99	0.71	0.48	-0.12	0.99	0.38	0.36	0.05	0.41		0.71	0.11	0.44	-0.4	-0.23	0.27	-0.21	-0.18
Intangible Assets	0.94	0.44	0.71	0.9	0.79	-0.55	0.2	0.65	0.63	0.98	0.57	-0.35	0.63	0.74	0.74	-0.12	0.79	0.71		0.24	0.57	-0.25	-0.3	0.42	-0.34	-0.29
Short Long Term Debt Total	0.28	0.12	0.42	0.18	0.53	0.16	0.5	0.64	0.05	0.33	0.59	-0.47	0.05	0.7	0.54	-0.46	0.6	0.11	0.24		0.31	0.46	-0.55	0.64	-0.55	-0.56
Net Receivables	0.63	0.68	0.76	0.58	0.56	-0.24	-0.02	0.4	0.34	0.69	0.14	-0.19	0.34	0.44	0.3	0.08	0.67	0.44	0.57	0.31		-0.24	0.03	0.39	-0.03	0.03
Short Term Debt	-0.29	0.11	0.05	-0.36	-0.12	0.39	0.86	-0.06	-0.38	-0.21	-0.08	-0.7	-0.38	0.14	0.07	-0.87	0.09	-0.4	-0.25	0.46	-0.24		-0.51	0.53	-0.52	-0.5
Common Stock	-0.35	0.0	-0.17	-0.33	-0.54	0.11	-0.69	-0.39	-0.19	-0.35	-0.39	0.73	-0.19	-0.48	-0.59	0.63	-0.31	-0.23	-0.3	-0.55	0.03	-0.51		-0.57	0.81	0.94
Inventory	0.46	0.26	0.42	0.4	0.62	-0.12	0.73	0.41	0.22	0.5	0.27	-0.8	0.22	0.55	0.55	-0.65	0.52	0.27	0.42	0.64	0.39	0.53	-0.57		-0.44	-0.63
Net Tangible Assets	-0.34	-0.06	-0.26	-0.3	-0.45	0.07	-0.71	-0.38	-0.17	-0.37	-0.46	0.71	-0.17	-0.48	-0.57	0.76	-0.4	-0.21	-0.34	-0.55	-0.03	-0.52	0.81	-0.44		0.78
Common Stock Shares Outstanding	-0.33	0.06	-0.12	-0.31	-0.54	0.05	-0.67	-0.39	-0.14	-0.34	-0.4	0.73	-0.14	-0.48	-0.58	0.62	-0.28	-0.18	-0.29	-0.56	0.03	-0.5	0.94	-0.63	0.78

Click cells to compare fundamentals

Biodexa Pharmaceticals Account Relationship Matchups

Biodexa Pharmaceticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Other Current Liab	2.4M	1.2M	1.3M	5.0M	4.5M	2.5M
Total Current Liabilities	3.0M	1.8M	1.9M	5.6M	5.0M	3.8M
Total Stockholder Equity	6.7M	10.5M	3.2M	4.7M	4.2M	4.0M
Property Plant And Equipment Net	542K	1.2M	831K	571K	513.9K	488.2K
Net Debt	(7.3M)	(9.3M)	(2.2M)	(5.5M)	(6.3M)	(6.6M)
Retained Earnings	(122.4M)	(127.8M)	(135.3M)	(144.8M)	(130.3M)	(123.8M)
Accounts Payable	337K	485K	339K	314K	282.6K	268.5K
Cash	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Assets Total	542K	1.2M	837K	3.5M	3.2M	3.0M
Non Currrent Assets Other	2.6M	(542K)	(1.2M)	(837K)	(753.3K)	(715.6K)
Cash And Short Term Investments	7.5M	10.1M	2.8M	6.0M	5.4M	8.0M
Non Current Liabilities Total	110K	619.5K	463K	295K	265.5K	252.2K
Other Current Assets	258K	607K	376K	355K	319.5K	303.5K
Other Stockholder Equity	74.4M	85.2M	83.7M	86.7M	99.7M	59.2M
Total Liab	3.1M	2.5M	2.4M	5.9M	5.3M	5.8M
Total Current Assets	9.3M	11.8M	4.7M	7.0M	6.3M	10.0M
Intangible Assets	10.1M	10.1M	6K	2.9M	2.6M	2.5M
Short Long Term Debt Total	260K	766K	624K	464K	417.6K	396.7K
Net Receivables	95K	33K	329K	704K	633.6K	455.7K
Liabilities And Stockholders Equity	9.8M	12.9M	5.5M	10.5M	9.5M	9.0M
Accumulated Other Comprehensive Income	53.7M	53.5M	53.0M	61.5M	70.8M	53.6M
Short Term Debt	200K	146K	161K	169K	152.1K	144.5K
Common Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Common Stock Shares Outstanding	5.4K	10.1K	12.4K	31.6K	36.3K	38.1K
Capital Lease Obligations	153K	766K	624K	464K	417.6K	504.3K
Net Invested Capital	6.8M	10.5M	3.2M	4.7M	4.2M	7.9M
Property Plant And Equipment Gross	2.1M	2.8M	2.5M	2.3M	2.1M	2.8M
Capital Stock	63K	98.5K	1.1M	1.2M	1.4M	1.4M
Net Working Capital	6.3M	9.9M	2.8M	1.5M	1.3M	1.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biodexa Free Cash Flow Yield vs Cash Flow To Debt Ratio Analysis

Free Cash Flow Yield vs Cash Flow To Debt Ratio

Free Cash Flow Yield vs Cash Flow To Debt Ratio Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Cash Flow To Debt Ratio

Biodexa Pharmaceticals fundamental ratios Correlations

Biodexa Pharmaceticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodexa Pharmaceticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Intangible Assets	+ 0.98	Non Current Assets Total
Non Current Assets Total	+ 0.96	Total Assets

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Total Current Assets	- 0.93	Net Debt
Other Assets	- 0.91	Retained Earnings
Short Term Debt	- 0.87	Other Stockholder Equity